Jordan M Chinai, B.S.
Department of Microbiology & Immunology
Albert Einstein College of Medicine
Forchheimer Building, Room 405
Bronx, NY 10461
Jordan received his B.S. in Biochemistry from Trinity University in 2010. While there, he worked in the laboratory of Adam R. Urbach and characterized a novel method of selective insulin detection. This work may have broader implications for the rational design of selective synthetic receptors. Jordan also spent a summer working in the laboratory of John B. MacMillan at UT Southwestern Medical Center in Dallas where he did research in natural product medicinal chemistry. During his time there he extracted, purified, and characterized an antibiotic from the sponge, Agelas citrina. Jordan joined the MD-PhD program at Albert Einstein College of Medicine in 2010. He is currently in the Zang lab studying new pathways for T cell costimulation and coinhibition. His goal is to advance our understanding of immune regulation in hopes of discovering new therapeutic targets for autoimmune disorders.
Cheng H, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clinical Cancer Research, in press
Koirala P, Roth M, Gill J, Chinai J, Ewart M, Piperdi S, Geller D, Hoang B, Fatakhova K, Ghorpade M, Zang X, Gorlick R. HHLA2, a new immune checkpoint member of the B7 family, is highly expressed in human osteosarcoma and associated with metastases and worse survival. Scientific Reports, in press
Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 36:587-595, 2015
Janakiram M*, Chinai JM*, Zhao A, Sparano JA, Zang X. HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families. OncoImmunology, 4: e1026534-1- e1026534-3, 2015
(* co-first authors)
Janakiram M*, Chinai JM*, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E, Jeon H, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clinical Cancer Research, 21:2359-2366, 2015
(* co-first authors)
Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS, Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, Zang X. Structure and cancer immunotherapy of the B7 family member B7x. Cell Reports, 9:1089-1098, 2014
Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A, Scharff MD, Zang X. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Proceedings of the National Academy of Sciences USA, 110:9879-9884, 2013.
Sroubek J, Krishnan Y, Chinai J, Buhl S, Scharff MD, McDonald TV. The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel. Journal of Immunological Methods, 375: 215-222, 2012
Chinai JM, Taylor AB, Ryno, LM, Hargreaves ND, Morris CA, Hart PJ, Urbach AR. Molecular recognition of insulin by a synthetic receptor. Journal of the American Chemical Society, 133:8810-8813, 2011